Preclinical Development: Linking the Lab to Human Trials

Contributed by:

Denise Myshko

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

The challenge of pharmaceutical discovery and development as a whole is that a large number of conditions need to be met in order for a single molecular entity to successfully reach the market, says Thomas Jones, Ph.D., senior director, toxicology and pathology, Eli Lilly and Company. “The molecule needs to have the appropriate specificity and potency against the intended targets, it needs the right biopharmaceutical and ADME characteristics to be absorbed and reach the site of action, it needs to be able to be manufactured, and of course it needs to be… Sidebar: Microdosing: A Compelling Advantage Experts on this topic Thomas Jones, Ph.D., Senior Director, Toxicology and Pathology, Eli Lilly and Company Jean-Jacques Garaud, M.D., Global Head, Pharmaceutical Research and Early Development, Roche Peter Smith, Ph.D., Senior VP, Nonclinical Development Sciences at Millennium Pharmaceuticals Inc.: The Takeda Oncology Company Alain Stricker-Krongrad, Ph.D., Chief Scientific Officer at Charles River

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK